Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PICASSO
2024-516100-42-00Phase 2Completed
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Mar 2022
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in melanoma comparing MaaT013 + ipilimumab + nivolumab with Placebo + ipilimumab + nivolumab (with crossover option) (2 arms). Primary endpoint: Safety: treatment-related Grade 3-4 adverse events. Started Mar 2022; status: completed.
02
Drugs
MaaT013
03
Conditions
melanoma
Beyond the preview
Go deeper on 2024-516100-42-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516100-42-00.